Overview

Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia

Status:
Recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

Patients with Acute Coronary Syndrome associated with de novo atrial fibrillation are randomized to benefit from either a conventional therapy associating dual antiplatelet therapy (DAPT) and anticoagulant or DAPT and an implantable monitoring device with a follow-up by telecardiology

Phase:

Phase 4

Details

Lead Sponsor:

Centre Hospitalier de PAU

Treatments:

Anticoagulants